The determination of serum biomarkers was carried out by Milliplex Map Human Circulation Biomarker Kit. PD-L1 was determined using the Human ProcartaPlexÔ Kit; oncomarker CA 72-4 was identified using ELISA. Concentrations are indicated in pg/ ml. Statistic processing included Kruskal-Wallis and Mann-Whitney analysis. Informed consent was obtained for the examination of patients.Results: A group of patients with first-time diagnosis of colorectal cancer (n¼215) took part in the investigation. The average age: (Nf [25%;75%]) 66.6 years old [62;72] 45% men and 55% women. Biomarker blood test was done prior to surgery. The control group included 53 healthy participants aged 47 [43;57]. The comparison group included 55 patients aged 59,5 [53,3;65] with inflammatory intestinal diseases. The patients were divided into subgroups: with the presence of invasive growth (n¼69) and with its absence (n¼153). In none of the cases did the biomarkers studied reveal significant differences in the content between the group of healthy individuals and those with non-cancerous bowel diseases. Classical markers CA 19-9 (12,0 [5,46;18,70], p< 0,0001) rose equally in both groups in CRC, with no difference between the groups. Markers such as CYFRA21-1 (1416,14 [906,1; 2213,68], p< 0,001) and OPN (6121 [3970; 11536], p¼0,001) in the group with invasive growth of CRC significantly differed both from the control group and from the comparison group, however, they did not differ between the groups with invasive and non-invasive tumor growth. An increase in the serum level of the PDL-1 in the group with invasive CRC reached significance with the control group (but not the comparison group), but it also almost did not differ within the group with CRC. VEGF (115,33 [90,6; 156,0], p¼0,0016) behaves atypically in our study, as it grew significantly in the group with non-invasive growth compared with the group with invasive growth; it was almost identical to non-oncological groups. The serum level of sFASL (57,63 [44,17; 86,86], p¼0,0001) but not sFAS,) behaved similarly, reaching a maximum in the group with non-invasive tumor growth. Conclusion:We found a relationship between the presence of invasion and the rates of biomarkers (sFASL) in the Kazakh population.

Patient Survey (GPS) on Lymphomas and CLL to describe the global differences in patients' information experiences at diagnosis, as well as to compare the areas of need for more information. Methods: Globally, 9,179 patients with lymphoma or CLL from 89 countries took part in the LC 2020 GPS. The countries were grouped into regions, and regions with greater than 200 patient respondents were included in the analysis. The five regions analysed were Asia (AS) (n = 2326), Oceania (OC) (n = 695), Europe (EU)(n = 4343), North America (NA) (n = 1543), and South America (SA) (n = 214).Descriptive analyses of questions relating to patients' information experiences at diagnoses and areas in which they needed more information were performed in IBM SPSS v27.Results: All the regions differed significantly (p < 0.05) in the demographic categories of age, sex, education level, and household status.When asked which time point patients had the greatest need for information, over half of patients in all the regions reported the time point as 'within the first month following diagnosis' (AS-62%, OC-58%, EU-57%, NA-53% and SA-59%) (Table 1).Relating to how patients felt about the amount of information they were given upon diagnosis with lymphoma, patients from AS were the most prevalent in reporting they were not given enough information (55%) followed by patients from NA (36%). Additionally, only 30% of patients from AS reported receiving the right amount of information, while 60% and more, of patients from NA, EU, SA, and OC reported the same (60%, 67%, 71% and 70% respectively) (Table 1).When asked about the specific areas patients needed more information in, the most commonly reported areas in all the regions were 'treatment options' (AS-76%, OC-44%, EU-50%, NA-61% and SA-40%), 'diagnosis and what it means' (AS-58%, OC-45%, EU-56%, NA-51% and SA-38%), and 'treatment side-effects' (AS-61%, OC-44%, EU-45%, NA-38% and SA-41%). Patients also reported needing information on 'support for self care', 'psychological support', 'support for their families', and 'fertility' (Table 1). Only 2% of patients from AS reported not needing any additional information compared to the other regions (OC-19%, EU-11%, NA-16% and SA-18%) (Table 1). Conclusion:Access to timely and credible medical information remains an essential aspect of a successful patient experience and this study shows that patients with lymphoma have diverse information experiences and needs. It is therefore important that doctors provide information that address(es) each patient's unique information needs.In the future, LC would like to explore how demographic differences may have confounded results.

No abstract

514 Background: Gastroenteropancreatic neuroendocrine tumors (GEP NET´s) are infrequent tumors, with a variety of symptoms depending of the kind of peptide they secrete as well as the affected organs. Long acting somatostatin analogues have shown an adequate rate of symptom control in functional tumors, they also have demonstrated antiproliferative effect, which is translated in a significant improvement of progression free and overall survival Methods: In this retrospective analysis of patients with metastatic GEP NET treated with long acting somatostatin analogues as first line, treated between 2005 and 2015, we evaluated clinical and pathological features, symptoms, disease control and survival adjusted with OMS classification Results: Our cohort included 95 patients with a mean age of 53 years. Primary affected sites were midgut (29.4%), followed by pNET (17.%), stomach (14.7%), and primary unknown in 14%. 20% of cases were functional tumors with diarrhea as the most common symptom in 70% and flushing in 50%. Considering the whole cohort the most prevalent symptom was abdominal pain in the 50% of cases. The OMS classification showed low grade tumors in 65% and 35% intermediate grade. Most common metastatic organ sites were; liver only 35%, liver and other 30%, peritoneum 10% and lymph nodes in 6%, non-specified sites in 19%. Somatostatine analogues used in first line were octreotide in 80% and lanreotide in 20%. Survival results demonstrated a progression free survival for the whole cohort of 84months. No differences between lanreotide and octreotide were observed. Conclusions: This study represents the first Mexican cohort of patients with GEP NET’s treated with somatostatin analogues with a long follow up.

No abstract